**Development of molecular marker linked with Cercospora Leaf spot (CLS) disease resistance in *Vigna radiata*, its cloning, and expression for evaluating antifungal activity against *Cercospora canescens***

**Maria Babar1, Siddra Ijaz1\*, Imran Ul Haq2, and Muhammad Sarwar Khan1**

**1Centre of Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture Faisalabad, Pakistan.**

**2Department of Plant Pathology, University of Agriculture Faisalabad, Pakistan**

**\*Corresponding author: siddraijazkhan@yahoo.com**

**Supplementary Table 1:** The phenotypic screening data of mungbean population

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Sr. #** | **Mungbean genotypes** | **Symptoms after one week of inoculation**  **(Foliage damage/lesions)** | **Symptoms after two weeks of inoculation**  **(Foliage damage/ lesions)** | **Symptoms after four weeks of inoculation**  **(Foliage damage/ lesions)** | **Symptoms after six weeks of inoculation**  **(Foliage damage/ lesions)** | **Rating scale** | **Plant response in greenhouse** | **Plants response according to literature** |
| 1 | NM 98 | No symptoms | No symptoms | 5% | 6% | 1 | HR | HR |
| 2 | NM 92 | No symptoms | No symptoms | 10% | 12% | 3 | R | R |
| 3 | NM 51 | No symptoms | 1% | 10% | 15% | 3 | R | R |
| 4 | NM 54 | No symptoms | No symptoms | 15% | 17% | 3 | R | T |
| 5 | Ramzan Mung | No symptoms | No symptoms | 8% | 7% | 1 | HR | ------------- |
| 6 | Kabuli Mung | 5% | 25% | 80% | 90% | 9 | HS | S |
| 7 | AZRI Mung 2006 | 1% | 1% | 25% | 15% | 3 | R | R |
| 8 | AZRI Mung 2018 | No symptoms | 1% | 5% | 8% | 1 | HR | HR |
| 9 | NM 2016 | 1% | 25% | 80% | 90% | 9 | HS | -------------- |
| 10 | Karak Mung-1 | 1% | 5% | 25% | 30% | 5 | MR | -------------- |
| 11 | Tashqand Mung | 1% | 1% | 20% | 30% | 5 | MR | -------------- |
| 12 | BM 2017  (Bahawalpur Mung-17) | 5% | 25% | 40% | 50% | 7 | S | -------------- |
| 13 | NM 2011 | No symptoms | No symptoms | 12% | 15% | 3 | R | R |
| 14 | VC-686 | No symptoms | 1% | 11% | 18% | 3 | R | -------------- |
| 15 | NCM 255-8 | 5% | 40% | 85% | 95% | 9 | HS | -------------- |
| 16 | NCM 251-4 | 5% | 25% | 80% | 90% | 9 | HS | -------------- |
| 17 | MH 10006 | 1% | 1% | 25% | 30% | 5 | MR | -------------- |
| 18 | NM 65-35-1 | No symptoms | No symptoms | 23% | 28% | 5 | MR | -------------- |
| 19 | NM 94 | No symptoms | 1% | 25% | 30% | 5 | MR | -------------- |
| 20 | MH 10023 | 1% | 25% | 40% | 50% | 7 | S | -------------- |
| 21 | MH10003 | No symptoms | No symptoms | 8% | 10% | 1 | HR | -------------- |
| 22 | NM 30A-2 | No symptoms | 1% | 25% | 30% | 5 | MR | -------------- |
| 23 | NM 04-3-1 | No symptoms | 1% | 22% | 30% | 5 | MR | -------------- |
| 24 | MH 11007 | No symptoms | 1% | 25% | 30% | 5 | MR | -------------- |
| 25 | NM 0117 | No symptoms | 1% | 25% | 30% | 5 | MR | -------------- |
| 26 | NCM 252-10 | 5% | 25% | 45% | 50% | 7 | S | -------------- |
| 27 | NM 46-5-2-11 | 5% | 40% | 42% | 50% | 7 | S | -------------- |
| 28 | NM 6-29-1 | No symptoms | No symptoms | 5% | 7% | 1 | HR | -------------- |
| 29 | MH 10005 | No symptoms | 1% | 6% | 8% | 1 | HR | -------------- |
| 30 | NM 0183 | No symptoms | 8% | 25% | 30% | 5 | MR | -------------- |
| 31 | NM 05-1-2 | 1% | 25% | 40% | 50% | 7 | S | -------------- |
| 32 | NM 42-11-4-1 | No symptoms | 5% | 25% | 30% | 5 | MR | -------------- |
| 33 | MH 11008 | No symptoms | 5% | 25% | 30% | 5 | MR | -------------- |
| 34 | MH 10010 | No symptoms | 1% | 25% | 30% | 5 | MR | -------------- |
| 35 | NM 046 | No symptoms | 5% | 25% | 30% | 5 | MR | -------------- |
| 36 | P 26 (13-21) | 5% | 40% | 45% | 50% | 7 | S | -------------- |

\*HR=Highly Resistant; R=Resistant; MR=Moderately Resistant; T=tolerant; S=Susceptible; HS=Highly Susceptible